Overspending driven by oversized single dose vials of cancer drugs

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Bach, Peter B ^a   Conti, Rena M ^b   Muller, Raymond J ^a   Schnoarr, Geoffrey C ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CARFILZOMIB; IPILIMUMAB; PEMBROLIZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; PRESCRIPTION DRUG;

ARTICLE; CANCER THERAPY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; LEUKEMIA; MULTIPLE MYELOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION; COST CONTROL; DRUG PACKAGING; ECONOMICS; EUROPEAN UNION; FEE; NEOPLASMS; UNITED STATES;

ANTINEOPLASTIC AGENTS; COST CONTROL; DRUG COSTS; DRUG PACKAGING; EUROPEAN UNION; HUMANS; NEOPLASMS; PRESCRIPTION DRUGS; PRESCRIPTION FEES; UNITED STATES;

EID: 85026971891     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i788     Document Type: Article

References (22)

1. Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA 2012;307:1513-6. doi:10.1001/jama.2012.362. 22419800.
2. Lien K, Cheung MC, Chan KK. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract 2015 Sep 1 JOP.2015.005876.
3. Smith RS. A 2-year retrospective review of vial sharing options for the compounding of cytotoxics. Eur J Hosp Pharm 2015;22:161-4doi:10.1136/ejhpharm-2014-000547. .
4. United States Pharmacopeia, ed. USP Guidebook to pharmaceutical compounding-sterile preparations. United States Pharmacopeial Convention, 2008.
5. Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res 2014;14:57. doi:10.1186/1472-6963-14-57. 24507545.
6. IMS Institute for Healthcare Informatics. Medicines use and spending shifts: a review of the use of medicines in the US in 2014. 2015. www.imshealth.com/en/thought-leadership/ims-institute/reports/medicines-use-in-the-us-2014.
7. US Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2015. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
8. US Department of Health and Human Services. National health and nutrition examination survey. Health professionals home interview Hyattsville. Centers for Disease Control and Prevention, National Centers for Health Statistics, 2004.
9. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2011. National Cancer Institute, 2014.
10. Center for Medicare and Medicaid Services. Medicare Part B drug average sales price: manufacturer reporting of average sales price (ASP) data. 2015. www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html
11. European Medicines Agency. EPAR summary for the public: Velcade 2015. www.ema. europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/000539/WC500048136.pdf.
12. Newcomer LN. Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Aff (Millwood) 2012;31:780-5. doi: 10.1377/hlthaff.2012.0002. 22492895.
13. Office of Inspector General. Part B payments for 340B-purchased drugs. 2015. Available from: http://oig.hhs.gov/oei/reports/oei-12-14-00030.pdf.
14. Conti RM, Bach PB. Cost consequences of the 340B drug discount program. JAMA 2013;309:1995-6. doi:10.1001/jama.2013.4156. 23609758.
15. Conti RM, Bach PB. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities. Health Aff (Millwood) 2014;33:1786-92. doi:10.1377/hlthaff.2014.0540. 25288423.
16. Kaiser Family Foundation. Medigap reform: setting the context for understanding recent proposals. 2014 http://kff.org/medicare/issue-brief/medigap-reform-setting-the-context/.
17. US Food and Drug Administration. Code of federal regulations-title 21-food and drugs. FDA, 2013.
18. Centers for Medicare and Medicaid Services. Safe use of single dose/single use medications to prevent healthcare-associated infections. 2012 www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-12-35.pdf.
19. Centers for Disease Control and Prevention. Protect patients against preventable harm from improper use of single-dose/single-use vials. 2012 www.cdc.gov/injectionsafety/CDCposition-SingleUseVial.html.
20. USDHHS. FDA, CDER, CBER. Allowable excess volume and labeled vial fill size in injectable drug and biological products: guidance for industry. 2015. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389069.pdf.
21. Centre for Medicare and Medicaid Services. Safe use of single dose/single use medications to prevent healthcare-associated infections. www.cms.gov/Medicare/Provider-Enrollmentand-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-12-35.pdf.
22. CDC. Protect patients against preventable harm from improper use of single-dose/single-use vials. 2012. www.cdc.gov/injectionsafety/CDCposition-SingleUseVial.html.